ReviR Therapeutics Announces Funding Haul for Oral Genetic Treatments

Stock.adobe.com

ReviR Therapeutics announced that it has secured $30 million in Series A financing, which will be used to augment the company’s AI-powered drug discovery platform. The platform, VoyageR, will be identify potential new treatments for conditions like Huntington’s Disease, Chorcot-Marie-Tooth disease, and ALS.

ReviR’s strategy is focused on developing orally administered genetic therapies, which greatly reduces the burden of treatment on the actual patient. To achieve this, the company is focused on developing RNA therapies, which can be used to treat so-called un-druggable disease-related proteins.

In a press release, ReviR Therapeutics co-founder and CEO Dr. Peng Yue said, “Neurological diseases affect a large number of individuals worldwide, many of which do not have disease modifying therapies available. ReviR is dedicated to developing accessible, safer genetic therapies that can be administered orally. We value the support from new and existing investors as we progress from initial platform development to clinical trials, continually enhancing our AI platform and advancing our pipeline. As we move forward, we will continue to raise funds as an extension to our Series A to support additional programs entering clinical trials."

One of the newest investors in ReviR is XtalPi. In the same press release, the firm’s co-founder and chairman Dr. Shuhao Wen said, “At XtalPi, we recognize the immense potential of small molecule targeting RNA to significantly expand the boundaries of drug discovery. Our collaboration with ReviR, leveraging XtalPi's cutting-edge AI and robotics drug discovery solutions with ReviR's specialized capabilities in RNA structural analysis, small molecule screening, and target engagement evaluation, has already yielded promising pipeline results. Our collective expertise is aimed at propelling these innovations into clinical research, tapping into the vast and underexplored potential of RNA targets, and delivering effective novel therapeutic options to patients worldwide."

Mr. Zhihua Yu, founding partner of Lapam Capital, added, "Small molecule targeting RNA represents a highly challenging and innovative field. RNA targets offer greater potential compared to protein targets, but also present higher development difficulties. We have great confidence in ReviR's platform, which can identify potential RNA targets and efficiently develop safe and effective RNA-targeted therapies. This enables the development of orally administrable small molecule drugs for previously undruggable targets. ReviR has built a team with extensive experience in computational biology, RNA biology, and drug discovery, showcasing exceptional execution capabilities. We are confident the company will advance its pipeline to clinical trials soon, benefiting patients worldwide. We will continue to support ReviR with our experience and resources as it grows."

Source

1. ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders. ReviR Therapeutics. July 26, 2024. https://www.prnewswire.com/news-releases/revir-therapeutics-raises-30-million-series-a-financing-to-advance-its-proprietary-oral-genetic-medicines-for-multiple-cns-disorders-302206560.html